India Pharma Outlook Team | Thursday, 26 June 2025
AstraZeneca, a biopharmaceutical company, announced on Thursday that it had invested Rs 166 crore to expand its global center in Bengaluru, adding 400 positions to support AI innovation, global services, and research & development.
According to a statement from AstraZeneca, the new building will house up to 1,300 workers, including 400 new positions, supporting the company's strengths in AI-powered innovation across R&D, global business services, IT, and digital health operations.
"Our global hub in Bengaluru is a strategic investment that will play a vital role in advancing AstraZeneca's bold ambition to deliver 20 new medicines by 2030 -- by strengthening automated, scalable, data-driven, and patient-centric solutions," AstraZeneca Vice President, Global Business Services, Jackie Crockford said. Within a year after the establishment of its Global Innovation and Technology Centre (GITC) in Chennai, AstraZeneca has made two significant investments in India.
"The combined workforce now at AstraZeneca India Pvt Ltd (AZIPL) will reach close to 4,000 employees, strengthening the company's capability to deliver life-changing medicines to patients worldwide," the company said.
Also Read: Aurobindo's CuraTeQ Gets UK MHRA Nod for Biosimilar Dyrupeg
AstraZeneca is focused on transforming healthcare for millions of people in India. In addition to its innovative portfolio in specialist disease areas including oncology, cardio-vascular, respiratory and rare disease, the company has a strong hub for technology as well as research and development in India. Including the GITC, it employs more than 4000 in the country and is continuously shaping talent that is skilled, diverse and future ready.
, CDSCO.jpg)
